Using case-based presentations, this program will assist Advanced Practice Clinicians (APC: PA & NP) in defining what constitutes an acute relapse versus a pseudo-relapse in patients with multiple sclerosis (MS) and discussing therapeutic options. We will discuss the currently available FDA-approved Disease Modifying Therapies (DMT), their pharmacologic properties and recommended monitoring. Using evidence-based medicine, we will outline an approach to starting a DMT after diagnosis and switching a DMT if necessary, due to breakthrough activity.
[learn_press_profile]